Voyager Therapeutics Inc (VYGR) financials
Voyager Therapeutics revenue and earnings by year
Voyager Therapeutics's revenue was $40.4 million in the fiscal year to December 31, 2025, down 49.5% from the year before. Net income was -$120 million, -296.5% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 12.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 80 | 250 | 41 | 37 | 171 | 104 | 8 | 10 | 14 |
| Revenue growth | -49.5% | -68.0% | 511.2% | 9.3% | -78.1% | 63.9% | 1270.1% | -24.8% | -28.7% | — |
| Operating income | -132 | -83 | 122 | -51 | -74 | 27 | -52 | -91 | -72 | -41 |
| Operating margin | -326.6% | -104.1% | 48.8% | -124.3% | -196.8% | 16.0% | -49.5% | -1195.6% | -709.1% | -290.4% |
| Net income | -120 | -65 | 132 | -46 | -71 | 37 | -44 | -88 | -71 | -40 |
| Net margin | -296.5% | -81.3% | 52.9% | -113.4% | -190.3% | 21.5% | -41.8% | -1158.8% | -697.6% | -282.7% |
| Diluted EPS | -$2.04 | -$1.13 | $2.97 | -$1.21 | -$1.89 | $0.96 | -$1.27 | -$2.75 | -$2.64 | -$1.59 |
| Free cash flow | -135 | -19 | 75 | -15 | -55 | -109 | 41 | -20 | -65 | -48 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open VYGR in Markets.
See also: VYGR returns
No forecast, no recommendation. This page describes Voyager Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.